FORT WORTH, TX, Aug. 03, 2022 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “us,” or “our”) (NASDAQ:SMTI), a provider of and technologies for the treatment of surgical and chronic wounds dedicated to improving patient outcomes, today announced details of its earnings release for the second quarter ended June 30, 2022.
Sanara will release its results after market close on Monday, August 15, 2022 and will host a conference call on Tuesday, August 16, 2022 at 9:00 a.m. EST. The toll-free number to call for this conference call is 888-506-0062 (international callers: 973-528-0011) and the pass code is 265953. A telephone replay of the conference call will be available until Tuesday, 30 August 2022. , by dialing 877-481-4010 (international callers: 919-882-2331) and entering the replay passcode: 46300.
A live webcast of Sanara’s conference call will be available in the Investor Relations section of the company’s website, www.SanaraMedTech.com. A one-year online replay will be available after the live stream ends.
About Sanara MedTech Inc.
With a focus on improving patient outcomes through evidence-based healing solutions, Sanara MedTech Inc. markets, distributes and develops wound and skin care products for use by physicians and clinicians in hospitals, clinics and all post-acute care facilities and offers wound care and virtual dermatology consultation services via telemedicine. Sanara’s products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara MedTech markets and distributes CellerateRX® Surgical Activated Collagen®, FORTIFY TRG™ Tissue Repair Graft and FORTIFY FLOWABLE™ Extracellular Matrix as well as a portfolio of advanced biologics focused on AMPLIFY™ Verified Inductive Bone Matrix, ALLOCYTE™ Advanced Cellular Bone Matrix, BiFORM ® Bioactive Moldable Matrix and TEXAGEN™ Amniotic Membrane Allograft to the surgical market. In addition, the following products are sold in the wound care market: BIAKŌS™ Antimicrobial Skin and Wound Cleanser, BIAKŌS™ Antimicrobial Wound Gel, BIAKŌS™ Antimicrobial Skin and Wound Irrigation Solution and HYCOL™ hydrolyzed collagen. Sanara’s pipeline also contains potentially transformative product candidates for opportunistic pathogen and biofilm attenuation, wound re-epithelialization and closure, necrotic tissue debridement, and cell compatible substrates. The Company believes that it has the ability to move its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships focused on products that improve results at a lower overall cost. Additionally, Sanara is actively seeking to grow in its six priority areas of wound and skin care for the acute, post-acute and surgical markets. Focus areas are Debridement, Biofilm Removal, Hydrolyzed Collagen, Advanced Biologics, Negative Pressure Wound Therapy Complementary Products, and Oxygen Delivery Systems segment of the medical industry. Health care.
Information about forward-looking statements
Statements contained in this press release that do not constitute historical facts are “forward-looking statements,” within the meaning of and subject to the safe harbor created by the Private Securities Litigation Reform Act of 1995. Such statements can be identified by terms such as “aim”, “anticipate”, “believe”, “contemplate”, “continue”, “could”, “estimate”, “expect”, “intend”, “may” , “plan”, “potential”, “predict”, “preliminary”, “project”, “research”, “should”, “target”, “will” or “would”, or the negative forms of these terms, variations of these terms or other similar expressions. These forward-looking statements include, among other things, statements regarding our business strategy and mission, new product development, and expansion of the Company’s telehealth and wound care businesses. These elements involve risks, contingencies and uncertainties such as the uncertainties associated with the development and process of obtaining regulatory approval for new products, the magnitude of product demand, market acceptance and customers, the effect of economic conditions, competition, pricing, the ability to consume and integrate acquisitions and other risks, contingencies and uncertainties detailed in the Company’s filings with the SEC, which could cause The Company’s actual results of operations, performance, business plans or prospects differ materially from those expressed or implied by such statements.
All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect future circumstances or the occurrence of unforeseen events, unless applicable securities laws require it.
Callon Nichols, Director of Investor Relations 713-826-0524 [email protected]
SOURCE: Sanara MedTech Inc.